Takeda Oncology Pipeline

Our research and development efforts focus on advancing medicines for thoracic, gastrointestinal and hematologic cancers by leveraging modalities best suited to make a difference in the treatment of these diseases. Our core modalities include antibody-drug conjugate (ADCs), complex biologics, small molecules and gamma delta T cell therapies.

These therapies in development are investigational and have not been approved by any regulatory bodies for use in the investigational indications listed below.

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Brentuximab vedotin*	ADC	*Newly diagnosed Hodgkin lymphoma (EU)*	**Filed**	Pfizer and Takeda fund joint development costs on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs. Takeda has commercialization rights for the treatment outside of U.S. and Canada.
Dazostinag (TAK-676)	Small molecule	*Solid tumors*	**Phase 1/2**	STING agonist
Elritercept (TAK-226)†	Complex biologic	*Anemia-associated myelodysplastic syndromes*	**Phase 3**	Takeda has development and commercialization rights for the treatment worldwide outside of mainland China, Hong Kong and Macau.
		Anemia-associated myelofibrosis	**Phase 2**	
Mirvetuximab soravtansine-gynx (TAK-853)	ADC	*Folate receptor alpha (FRα)-positive platinum-sensitive ovarian cancer (JP)*	**Phase 3**	Takeda has development and commercialization rights for the treatment in Japan.
		Folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (JP)	**Phase 1/2**	

INVESTIGATIONAL THERAPY	MODALITY	INVESTIGATIONAL INDICATION	PHASE	ADDITIONAL INFORMATION
Rusfertide (TAK-121)	**Small molecule**	*Polycythemia vera (USA)*	**Phase 3**	Hepcidin mimetic peptide (injection)
TAK-012	**Gamma delta T cell therapy**	*Acute myeloid leukemia*	**Phase 1/2a**	
TAK-186	**Complex biologic**	*Solid tumors*	**Phase 1/2**	EGFR x CD3 targeting COBRA (COnditional Bispecific Redirected Activation) T cell engager immunotherapy
TAK-280	**Complex biologic**	*Solid tumors*	**Phase 1/2**	B7-H3 x CD3 targeting COBRA T cell engager immunotherapy

*Marketed products have received approval in one or more jurisdictions.
†Treatments have one or more clinical trials in active recruitment.
All programs have global development rights unless otherwise noted.
GL = global (USA, Europe, Japan, China) / EU = Europe / JP = Japan / CN = China / GEM = global emerging markets.

@TakedaOncology
Learn more at **TakedaOncology.com**

Takeda | ONCOLOGY